PP
NAGE

PDT Partners’s Niagen Bioscience NAGE Stock Holding History

PDT Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,243
Closed -$67K – 1186
2022
Q1 		$67K Sell
27,243
-40,913
-60% -$112K 0.01% 889
2021
Q4 		$255K Buy
68,156
+8,149
+14% +$44K 0.02% 719
2021
Q3 		$376K Sell
60,007
-15,177
-20% -$125K 0.03% 538
2021
Q2 		$741K Buy
+75,184
New +$656K 0.05% 425
2021
Q1 		– Sell
-10,738
Closed -$52K – 900
2020
Q4 		$52K Buy
+10,738
New +$52.3K ﹤0.01% 671

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PDT Partners's NAGE Position: Q2 2022 in Review

PDT Partners sold out of Niagen Bioscience (NAGE) in Q2 2022, closing a stake of 27,243 shares — an estimated $67K sold.

PDT Partners first reported a position in NAGE in Q4 2020 and held it in 5 quarters. The position peaked at $741K in Q2 2021. 75 funds tracked by Wall St. Rank hold NAGE as of Q2 2022.

  • PDT Partners reported no remaining Niagen Bioscience position as of Q2 2022 after selling out during the quarter.
  • PDT Partners sold 27,243 Niagen Bioscience shares in Q2 2022, an estimated $67K.
  • PDT Partners first reported a position in Niagen Bioscience in Q4 2020 and held it in 5 quarters.
  • PDT Partners's Niagen Bioscience position peaked at $741K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.